Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC–MS/MS approach
Our findings suggest that uVTN is a promising and non-invasive biomarker for the diagnosis and monitoring of MBC. While future validation in larger cohorts should be done, these results identify a novel urinary protein that represents the first non-invasive diagnostic test for monitoring BC progression and recurrence.
Authors
- Elisa M. Schunkert (ORCID: https://orcid.org/0000-0002-4388-8420)
- John C. Gebler (ORCID: https://orcid.org/0000-0003-0372-3725)
- Rama Aldakhlallah (ORCID: https://orcid.org/0009-0008-5833-0244)
- Marsha A. Moses (ORCID: https://orcid.org/0000-0003-3108-0704)
- David Zurakowski (ORCID: https://orcid.org/0000-0003-3610-6942)
- Steven J. Staffa (ORCID: https://orcid.org/0000-0002-7588-7596)
- Andrew El‐Hayek
- Susan Pories (ORCID: https://orcid.org/0000-0001-7315-9993)
- Adelle Dagher
- Petra Olivova
- Martin Gilár (ORCID: https://orcid.org/0000-0003-1199-1287)
- Scott Geromanos
- Margaret Lotz
- Guozhong Li (ORCID: https://orcid.org/0000-0001-5432-6178)
- Roopali Roy
Institutions
- Boston Children's Hospital (US)
- Mount Auburn Hospital (US)
- Harvard University (US)
- Waters (United States) (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1186/s13058-025-02053-2
- Citations
- 3
- Primary Topic
- Advanced Proteomics Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.27
Funders
- Breast Cancer Research Foundation
- Advanced Medical Research Foundation
- Boston Children's Hospital